Abstract:The incidence of diastolic dysfunction increases with age in both humans and mice. This is characterized by increased passive stiffness and slower relaxation of the left ventricle. The stiffness arises at least partially from progressively increased interstitial collagen deposition because of highly secretory fibroblasts. In the past, we demonstrated that AMPK activation via the drug 5-aminoimidazole-4-carboxamide riboside (AICAR) in middle-aged mice reduced adverse remodeling after myocardial infarction. Therefore, as an attempt to normalize the fibroblast phenotype, we used 21-mo-old male and female mice and treated them with AICAR (0.166 mg/g body wt) where each mouse was followed in a functional study over a 3-mo period. We found sex-related differences in extracellular matrix (ECM) composition as well as heart function indices at baseline, which were further accentuated by AICAR treatment. AICAR attenuated the age-related increase in left atrial volume (LAV, an indicator of diastolic dysfunction) in female but not in male hearts, which was associated with reduced collagen deposition in the old female heart, and reduced the transcription factor Gli1 expression in cardiac fibroblasts. We further demonstrated that collagen synthesis was dependent on Gli1, which is a target of AMPK-mediated degradation. By contrast, AICAR had a minor impact on cardiac fibroblasts in the old male heart because of blunted AMPK phosphorylation. Hence, it did not significantly improve old male heart function indices. In conclusion, we demonstrated that male and female hearts are phenotypically different, and sex-specific differences need to be considered when analyzing the response to pharmacological intervention.NEW & NOTEWORTHY The aging heart develops diastolic dysfunction because of increased collagen deposition. We attempted to reduce collagen expression in the old heart by activating AMPK using AICAR. An improvement of diastolic function and reduction of cardiac fibrosis was found only in the female heart and correlated with decreased procollagen expression and increased degradation of the transcription factor Gli1. Male hearts display blunted AICAR-dependent AMPK activation and therefore this treatment had no benefits for the male mice.

Soluble Receptor for Advanced Glycation End-products regulates age-associated Cardiac Fibrosis

Advanced Glycation End Product (Age)-Age Receptor (Rage) System Upregulated Connexin43 Expression In Rat Cardiomyocytes Via Pkc And Erk Mapk Pathways

AGEs Increased Migration and Inflammatory Responses of Adventitial Fibroblasts Via RAGE, MAPK and NF-κB Pathways

Sex-dependent deterioration of cardiac function and molecular alterations in age- and disease-associated RAGE overexpression

RAGE Upregulation and Nuclear Factor-Kappab Activation Associated with Ageing Rat Cardiomyocyte Dysfunction.

Age-Dependent RGS5 Loss in Pericytes Induces Cardiac Dysfunction and Fibrosis

Macrophage RAGE deficiency prevents myocardial fibrosis by repressing autophagy-mediated macrophage alternative activation

Retracted: Advanced Glycation Endproduct (AGE) Accumulation and AGE Receptor (RAGE) Up‐regulation Contribute to the Onset of Diabetic Cardiomyopathy

Increased Levels of sRAGE in Diabetic CKD-G5D Patients: A Potential Protective Mechanism against AGE-Related Upregulation of Fibroblast Growth Factor 23 and Inflammation

Abstract 10153: SIRT1 Activation Restores Cardioprotection in the Aged Heart Against Ischemia/Reperfusion Injury

Soluble Receptor for Advanced Glycation End Products: A Protective Molecule against Intramyocardial Lipid Accumulation in Obese Zucker Rats?

Receptor for Advanced Glycation End-Products Signaling Interferes with the Vascular Smooth Muscle Cell Contractile Phenotype and Function

G-MDSCs promote aging-related cardiac fibrosis by activating myofibroblasts and preventing senescence

Antifibrotic Properties of Receptor for Advanced Glycation End Products in Idiopathic Pulmonary Fibrosis.

The Senescent Heart—"Age Doth Wither Its Infinite Variety"

Sex-specific phenotypes in the aging mouse heart and consequences for chronic fibrosis

Genetic Deletion of Galectin-3 Exacerbates Age-Related Myocardial Hypertrophy and Fibrosis in Mice

Intra-coronary Administration of Soluble Receptor for Advanced Glycation End-Products Attenuates Cardiac Remodeling with Decreased Myocardial Transforming Growth Factor-Beta1 Expression and Fibrosis in Minipigs with Ischemia-Reperfusion Injury.

Soluble RAGE attenuates myocardial I/R injury by suppressing interleukin-6

Knockout RAGE alleviates cardiac fibrosis through repressing endothelial-to-mesenchymal transition (EndMT) mediated by autophagy

Activation of Receptor for Advanced Glycation End Products Contributes to Aortic Remodeling and Endothelial Dysfunction in Sinoaortic Denervated Rats.